Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total ...
In a first-of-its-kind clinical trial, UCLA scientists have shown it's possible to reprogram a patient's blood-forming stem cells to generate a continuous supply of functional T cells, the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results